Who is eligible for ketamine or SPRAVATO therapy
GLP-1s were associated with lower risk of new substance use disorder diagnoses Across alcohol, cannabis, cocaine, nicotine, opioids, and other drug categories, people who started a GLP-1 medication were less likely to receive a new substance use disorder diagnosis over the following 3 years relative to those who started the comparison diabetes medication, sodium-glucose cotransporter-2 inhibitor
For the thigh, most people have sufficient subcutaneous fat to inject without pinching
primary endpoint was 50% pain reduction at day 30, with additional sensory/quality of life measures [137]
As such, payers should consider: Starting members on tailored weight loss solutions before authorizing GLP-1 treatment coverage Covering holistic programs inclusive of GLP-1 therapies Including conditional terms that provide short-term coverage for GLP-1 patients and Transition patients on to longer-term sustainable programs, such as: Newtopias GLP-1 Sustain is a habit-changing platform that ensures short-term GLP-1 benefits last through long-term change, supporting an eventual positive ROI
